ʻOkoʻa ka manawa coagulation maʻamau o ke kino o ke kanaka ma muli o ke ʻano ʻike.
Eia kekahi mau ʻano ʻike maʻamau a me kā lākou mau pae kuhikuhi maʻamau e pili ana:
1 Ka manawa thromboplastin hapa i hoʻāla ʻia (APTT):
ʻO ka laulā kuhikuhi maʻamau he 25-37 kekona. Hōʻike nui ka APTT i ka hana o nā kumu coagulation VIII, IX, XI, XII, a pēlā aku i ke ala coagulation kūloko.
2 Manawa Prothrombin (PT):
ʻO ka waiwai kuhikuhi maʻamau he 11-13 kekona. Hoʻohana nui ʻia ka PT e loiloi i ka hana o nā kumu coagulation II, V, VII, X, a pēlā aku ma ke ala coagulation extrinsic.
3 Laki kūlike honua (INR):
ʻO ka pae kuhikuhi maʻamau ma waena o 0.8 a me 1.2. Ua helu ʻia ʻo INR ma muli o ka waiwai PT a hoʻohana ʻia e nānā i ka hopena therapeutic o nā anticoagulants waha (e like me warfarin) e hoʻohālikelike ai i nā hopena hoʻāʻo ma waena o nā keʻena hoʻokolohua like ʻole.
4 Fibrinogen (FIB):
ʻO ka pae kuhikuhi maʻamau he 2-4g/L. ʻO FIB kahi glycoprotein plasma i hana ʻia e ke akepaʻa a he kuleana koʻikoʻi kāna i ke kaʻina hana coagulation. Hoʻololi ʻia ia i fibrin ma lalo o ka hana a thrombin e hana i kahi clot koko.
Pono e hoʻomaopopo ʻia he ʻokoʻa paha nā lako hoʻāʻo a me nā reagents o nā keʻena hoʻokolohua like ʻole, a he ʻokoʻa iki paha nā waiwai kuhikuhi maʻamau. Eia kekahi, ʻo kekahi mau mea physiological (e like me ka makahiki, ke kāne, ka hāpai ʻana, a me nā mea ʻē aʻe) a me nā mea pathological (e like me ka maʻi akepaʻa, nā maʻi ʻōnaehana koko, ka lawe ʻana i kekahi mau lāʻau lapaʻau, a me nā mea ʻē aʻe) e hoʻopilikia pū i ka manawa coagulation. No laila, i ka wehewehe ʻana i nā hopena manawa coagulation, pono e hana ʻia kahi loiloi piha me ke kūlana kikoʻī o ka mea maʻi.
ʻO BEIJING SUCCEEDER TECHNOLOGY INC.
KA LAWELAWE HOʻOKOMO ʻANA I KA COAGULATION DIAGNOSIS
NOI NO NĀ REAGENTS ANALYZER
Ua komo nui ʻo Beijing Succeeder Technology Inc. (code stock: 688338) i ke kahua o ka ʻike ʻana i ka coagulation mai kona hoʻokumu ʻia ʻana i ka makahiki 2003, a ua kūpaʻa ʻo ia e lilo i alakaʻi ma kēia kahua. Me ke keʻena nui ma Beijing, he hui R&D, hana a kūʻai aku ikaika ka hui, e kālele ana i ka hana hou a me ka hoʻohana ʻana i ka ʻenehana ʻike thrombosis a me hemostasis.
Me kona ikaika loea koʻikoʻi, ua lanakila ʻo Succeeder i 45 mau palapala sila i ʻae ʻia, me 14 mau palapala sila i hana ʻia, 16 mau palapala sila hoʻohālike pono a me 15 mau palapala sila hoʻolālā. Loaʻa i ka hui he 32 mau palapala hoʻopaʻa inoa huahana lāʻau lapaʻau Papa II, 3 mau palapala hoʻopaʻa inoa Papa I, a me ka palapala hōʻoia EU CE no 14 mau huahana, a ua hala i ka palapala hōʻoia ʻōnaehana hoʻokele maikaʻi ISO 13485 e hōʻoia i ka maikaʻi a me ke kūpaʻa o ka maikaʻi o ka huahana.
ʻAʻole wale ʻo Succeeder kahi ʻoihana koʻikoʻi o ka Beijing Biomedicine Industry Leapfrog Development Project (G20), akā ua pae maikaʻi ʻo ia ma ka Science and Technology Innovation Board i ka makahiki 2020, e hoʻokō ana i ka hoʻomohala leapfrog o ka ʻoihana. I kēia manawa, ua kūkulu ka ʻoihana i kahi pūnaewele kūʻai aku ma ka ʻāina holoʻokoʻa e uhi ana i nā haneli o nā ʻelele a me nā keʻena. Kūʻai maikaʻi ʻia kāna huahana ma ka hapa nui o ka ʻāina. Ke hoʻonui nei hoʻi i nā mākeke ma waho a ke hoʻomaikaʻi mau nei i kona hoʻokūkū honua.
Kāleka ʻoihana
WeChat Kina